Status:
COMPLETED
Collection of Blood and Bone Marrow Samples From Select Patients With CML to Measure Minimal Residual Disease
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Leukemia
Eligibility:
All Genders
18+ years
Brief Summary
Although allogeneic stem cell transplantation is curative in CML, evidence of the BCR-ABL oncogene at low levels is still found in long-term follow-up of survivors. Such low levels of BCR-ABL post-tra...
Detailed Description
Although allogeneic stem cell transplantation is curative in CML, evidence of the BCR-ABL oncogene at low levels is still found in long-term follow-up of survivors. Such low levels of BCR-ABL post-tra...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Diagnosed with CML
- Age 18 years and older
- EXCLUSION CRITERIA:
- Less than 60 days from onset of CML directed treatment
- Unable to comprehend the investigational nature of the protocol participation or unable to sign their own consent document.
- Platelet count less than 50 times 10(9)/L (Bone marrow donors only)
- Pregnant or lactating
Exclusion
Key Trial Info
Start Date :
December 29 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 13 2011
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT00819143
Start Date
December 29 2008
End Date
July 13 2011
Last Update
July 2 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Heart, Lung and Blood Institute (NHLBI), 9000 Rockville Pike
Bethesda, Maryland, United States, 20892